Pharmafile Logo
Pharmafocus logo
Advanced Search

Halaven

Showing 15 posts of 20 posts found.

NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer

February 22, 2018
Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma

NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …

News

NICE refuses Eisai’s breast cancer drug in new indication

November 28, 2017
Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma

NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 9, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis

It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …

News
iqwigsmall

Eisai “cannot understand” German agency’s recommendation to reject Halaven

September 6, 2016
Manufacturing and Production, Research and Development Eisai, Germany, Halaven, IQWIG, german

Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …

News
halaven

Eisai’s Halaven recommended for European approval

April 4, 2016
Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma

Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …

News
halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015
Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …

News

NHS backtracks on Cancer Drugs Fund de-listings

March 12, 2015
Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus

NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …

News
Keytruda image

Merck and Eisai partner on cancer therapy trial

March 6, 2015
Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1

Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …

News
Eisai image

Eisai cancer drug performs in sarcoma disease

February 26, 2015
Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour

Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …

News

NHS drops 25 treatments from Cancer Drugs Fund

January 12, 2015
Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus

Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …

News

Eisai restates Halaven’s challenge to Roche’s Xeloda

September 30, 2013
Research and Development, Sales and Marketing ECC, Halaven, Roche, Xeloda

Eisai has updated research on its breast cancer drug Halaven in a renewed bid to establish the treatment as a …

News
Halaven image

UK at centre of Eisai plans

September 18, 2012
Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven

Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …

News
Halaven image

NICE rejects Halaven for breast cancer

April 3, 2012
Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …

News

NICE will not back Eisai’s Halaven

November 17, 2011
Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

News

NICE says no to breast cancer treatment Halaven

July 20, 2011
Sales and Marketing Eisai, Halaven, NICE

Eisai’s Halaven has been rejected by NICE in draft guidance for locally advanced or metastatic breast cancer. Halaven (eribulin) is …

News

Latest content

Roche to acquire Carmot Therapeutics for $2.7bn

December 4, 2023

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023